RTTNews | Sep 14, 2021 07:47AM EDT

07:47 Tuesday, September 14, 2021 (RTTNews.com) - Zai Lab Limited (ZLAB) announced Breakthrough Therapy Designation has been granted in in China for investigational bemarituzumab in first-line treatment of patients with FGFR2b overexpressing and human epidermal growth factor receptor-negative metastatic and locally advanced gastric and GEJ cancers in combination with modified FOLFOX6. The designation is supported by results from the phase 2 FIGHT study.

Zai Lab has an exclusive license to develop and commercialize bemarituzumab in Greater China. Zai Lab collaborated with Five Prime on the phase 2 FIGHT trial in Greater China.

Read the original article on RTTNews ( https://www.rttnews.com/3225501/zai-lab-reports-breakthrough-therapy-designation-for-bemarituzumab-in-china.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved